Issue 11, 2022

Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications

Abstract

Escherichia coli NISSLE 1917 (EcN) is a Gram-negative strain with many prominent probiotic properties in the treatment of intestinal diseases such as diarrhea and inflammatory bowel disease (IBD), in particular ulcerative colitis. EcN not only exhibits antagonistic effects on a variety of intestinal pathogenic bacteria, but also regulates the secretion of immune factors in vivo and enhances the ability of host immunity. In this review, the mechanisms of EcN in the remission of inflammatory bowel disease are proposed and recent advances on the functionalized EcN are compiled to provide novel therapeutic strategies for the prevention and treatment of IBD.

Graphical abstract: Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications

Article information

Article type
Review Article
Submitted
21 Jan 2022
Accepted
23 Apr 2022
First published
25 Apr 2022

Food Funct., 2022,13, 5914-5924

Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications

Z. Zhao, S. Xu, W. Zhang, D. Wu and G. Yang, Food Funct., 2022, 13, 5914 DOI: 10.1039/D2FO00226D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements